Avoid testicular volume for sexual staging post-gonadotoxic therapy
STEP 1 — Gather Information
Confirm patient is a male childhood cancer survivor with history of gonadotoxic therapy (alkylating agents, testicular radiotherapy, or similar). Collect clinical pubertal assessment (Tanner staging), serum testosterone (preferably LC‑MS/MS), luteinizing hormone (LH) levels drawn before 10:00 AM, and relevant treatment details (dose, timing).
STEP 2 — Rule In / Rule Out
Is the patient a male childhood cancer survivor previously exposed to gonadotoxic agents?
- Yes → proceed to Step 3 (testicular volume unreliable).
- No → testicular volume may be used per standard pubertal staging; no further action needed by this skill.
STEP 3 — Classify or Stratify
Classify that testicular volume is not a reliable primary or sole indicator of sexual maturation due to gonadotoxic injury to germ cells and Sertoli cells; rely instead on hormonal and clinical markers.
STEP 4 — Decide
Decide to assess sexual development using serum testosterone and LH levels in conjunction with clinical examination (e.g., Tanner staging), rather than testicular volume alone, to guide decisions about pubertal status and potential hormone replacement.
Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on testicular volume; reduced testis size may reflect germinal epithelium injury rather than central pubertal status. Elevated LH in this context often indicates primary gonadal injury, not onset of central puberty. Avoid misinterpreting prepubertal testicular volume as delayed central puberty without hormonal correlation.
Concrete Clinical Example
A 14‑year‑old male survivor of acute lymphoblastic leukemia treated with cyclophosphamide and testicular radiotherapy presents with absent pubertal changes. Testicular volume is 3 mL (prepubertal range). Serum testosterone is low and LH is markedly elevated, indicating primary gonadal injury. Using testicular volume alone would suggest delayed puberty; the correct interpretation is gonadal failure, leading to consideration of testosterone replacement after further evaluation.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175